SRT1720

Home
Ligands
SRT1720

Ligand id: 7703

Name: SRT1720

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	8
Hydrogen bond donors	2
Rotatable bonds	6
Topological polar surface area	115.69
Molecular weight	469.17
XLogP	3.54
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Classification
Compound class	Synthetic organic

IUPAC Name
N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide

IUPAC Name

N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide

Database Links
CAS Registry No.	925434-55-5
ChEMBL Ligand	CHEMBL257991
GtoPdb PubChem SID	223366036
PubChem CID	24180125
RCSB PDB Ligand	SR7
Search Google for chemical match using the InChIKey	IASPBORHOMBZMY-UHFFFAOYSA-N
Search Google for chemicals with the same backbone	IASPBORHOMBZMY
Search UniChem for chemical match using the InChIKey	IASPBORHOMBZMY-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone	IASPBORHOMBZMY
Wikipedia	SRT1720

Comments
SRT1720 is a selective SIRT1 activator. SRT1720 binds to the SIRT1 enzyme–peptide substrate complex at an allosteric site amino-terminal to the catalytic domain [2]. In vivo studies show that SIRT1 activation has the potential to improve insulin sensitivity in animal models of obesity, and improve glucose homeostasis [2]. This indicates the potential of such compounds as treatment for type II diabetes.

Comments

SRT1720 is a selective SIRT1 activator. SRT1720 binds to the SIRT1 enzyme–peptide substrate complex at an allosteric site amino-terminal to the catalytic domain [2]. In vivo studies show that SIRT1 activation has the potential to improve insulin sensitivity in animal models of obesity, and improve glucose homeostasis [2]. This indicates the potential of such compounds as treatment for type II diabetes.